BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Alcohol
,
Valproic acid
,
rs2476601
,
TGFB1
,
Apoptosis
,
Hepatitis
,
Lymphocyte
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
dmxaa
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Melanoma A375 xenografts with host mouse stromal tissue
Host stromal tissue and melanoma A375 xenografts
Stromal and cancer cells in melanoma xenografts before and after treatment with DMXAA
Stromal cells in melanoma xenografts before and after treatment with DMXAA
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Flavonoid derivative DMXAA attenuates cisplatin-induced acute kidney injury independent of STING sig…
A DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity.
DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.
Fever-range hyperthermia promotes cGAS-STING pathway and synergizes DMXAA-induced antiviral immunity…
p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupti…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of DMXAA (Now Known as ASA404) in Solid Tumors
Phase I Safety Study of DMXAA in Refractory Tumors
Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Smal…
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies o…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ